Genetic Testing Market Growth and Future Prospects

The global genetic testing market was valued at USD 19.73 Billion in 2024 and is projected to grow from USD 21.7 Billion in 2025 to reach USD 46.51 Billion by 2033, registering a robust CAGR of 10% during the forecast period. Genetic testing involves examining DNA to detect gene mutations linked with congenital disorders and several other diseases. Techniques such as cytogenetic testing, biochemical testing, molecular testing, and chromosome analysis help identify changes in chromosomes, genes, or proteins.

📥 Download Sample

Genetic Testing Market Growth Factors
Rise in Awareness and Acceptance of Personalized Medicines Personalized medicine is transforming healthcare by providing individualized treatment plans. Genetic testing, especially in pharmacogenomics, supports early disease detection and custom drug therapies. The demand for personalized treatment is increasing as patients actively request genetic tests for early detection and prevention, driving market growth.

Advancements in Genetic Testing Techniques Innovations like next-generation sequencing (NGS) and chromosomal microarray analysis have revolutionized the detection of genetic disorders. For example, Roche's FoundationOne Liquid test detects 70 common gene mutations in solid tumors, while Myriad Genetics’ FDA-approved BRACAnalysis CDx test identifies germline BRCA mutations in pancreatic cancer patients. Such technological developments continue to propel the market forward.

Market Restraining Factors
Stringent Regulatory Requirements Approval processes for genetic tests, regulated by the FDA and CE mark in Europe, are complex. Devices must comply with rigorous standards, making market entry challenging and restraining growth.

Market Opportunities
Untapped Emerging Markets Countries like India, China, and Brazil offer significant growth potential due to rising healthcare investments, large populations, and increased awareness of genetic disorders. For instance, Takara Bio USA expanded its GMP facility in Japan to manufacture gene and cell therapy products, highlighting market opportunities in Asia-Pacific.

Regional Insights
North America is the dominant region, accounting for 40% of the global market in 2019 and projected to reach USD 9,595 million by 2030 at a CAGR of 9%, driven by awareness campaigns and the presence of key players.
Europe is the second-largest market, estimated at USD 8,665 million by 2030 with a CAGR of 10%, fueled by patient awareness and genomics projects like the 100,000 Genomes Project.
Asia-Pacific is the fastest-growing region, expected to reach USD 6,000 million by 2030 at a CAGR of 9%, driven by a large population, increasing incidence of genetic disorders, and rising healthcare expenditure.

Type Analysis

• Predictive and Presymptomatic Testing is the fastest-growing segment, projected to reach USD 7,020 million by 2030 at a CAGR of 12%.

• Prenatal and Newborn Testing dominates the market, expected to reach USD 8,125 million by 2030 at a CAGR of 9%.

• Diagnostic Testing ranks third, projected at USD 5,075 million by 2030 with a CAGR of 8%.

Technique Analysis
DNA Sequencing dominates the market with a strong projected CAGR of 10.20%. Advancements in NGS, reduced sequencing costs, and growing demand for personalized medicine contribute to its rapid adoption.

Application Analysis
Oncology holds the largest market share due to its pivotal role in cancer diagnosis, treatment, and management. Genetic insights enable personalized therapies and improve clinical outcomes.

End-User Analysis
Hospitals & Clinics lead the market due to their central role in patient care and the integration of genetic testing in disease diagnosis, risk assessment, and personalized treatment plans.

Key Players in the Genetic Testing Market

• Tellmegen

• 24 Genetics

• AncestryDNA

• Igenomix

• Myriad Genetics, Inc.

• Illumina, Inc.

• Amgen, Inc.

• F. Hoffmann-La Roche Ltd.

• Abbott Laboratories

• Qiagen N.V.

• PerkinElmer

• DiaSorin S.p.A.

• Experteam s.r.l.

• Real Gene S.r.l.

• DNA SOLUTIONS

• Circle DNA

• MapmyGenome

Recent Developments
In April 2022, Bio-Rad Laboratories, Inc. launched antibodies specific to cemiplimab (Libtayo), enabling selective assays for bioanalysis and drug monitoring.

About Us:
Straits Research is a leading global market intelligence and consulting firm, dedicated to delivering actionable insights and in-depth analysis across a wide range of industries. Our mission is to empower organizations, investors, and decision-makers with reliable data, strategic guidance, and forward-looking perspectives to help them thrive in a rapidly evolving business landscape.

Contact Us:
Email: sales@straitsresearch.com
Tel: +1 646 905 0080 (U.S.), +44 203 695 0070 (U.K.)
Website: https://straitsresearch.com/